Femoston 1/10 & 2/10/Femoston Conti 1/5

Femoston 1/10: 14 white FC tab each containing Estradiol 1 mg, 14 grey FC tab each containing Estradiol 1 mg, dydrogesterone 10 mg. Femoston 2/10: 14 brick red FC tab each containing Estradiol 2 mg, 14 yellow FC tab each containing Estradiol 2 mg, dydrogesterone 10 mg. Femoston Conti 1/5: Each salmon tab containing Estradiol 1 mg, dydrogesterone 5 mg

Femoston 1/10 & 2/10 HRT for women w/ disorders due to natural- or surgically-induced menopause. Femoston Conti HRT for symptomatic relief of estrogen deficiency in women w/ uterus. Prevention of postmenopausal osteoporosis in women w/ uterus.

Femoston 1/10 1 white tab daily for 1st 14 days, followed by 1 grey tab daily for the next 14 days, continue w/o interruption. If patient is still menstruating, begin treatment on 1st day after onset of menstruation. Femoston 2/10 1 brick red tab daily for 1st 14 days, followed by 1 yellow tab daily for the next 14 days, continue w/o break between packs. Femoston Conti 1/5 1 tab daily, continue w/o break between packs.

May be taken with or without food.

Hypersensitivity. Previous or current VTE (DVT, pulmonary embolism); active or recent arterial thromboembolic disease (eg, angina, MI). Known past or suspected breast cancer, oestrogen-dependent malignant tumours (eg, endometrial cancer), progestogen-dependent neoplasms (eg, meningioma), thrombophilic disorders (eg, protein C, protein S or antithrombin deficiency). Undiagnosed genital bleeding; untreated endometrial hyperplasia; porphyria. Acute or history of liver disease where LFTs have not returned to normal.

Discontinue use if VTE develops; jaundice or liver function deterioration, significant increased BP, new onset of migraine-type headache occurs. Not intended for contraceptive use. Increased risk of endometrial hyperplasia & carcinoma; breast & ovarian cancer. Leiomyoma/uterine fibroids or endometriosis; risk factors for estrogen-dependent tumours eg, 1st-degree hereditary breast cancer; risk factors for VTE eg, use of oestrogens, older age, major surgery, prolonged immobilisation, obesity (BMI >30 kg/m²), SLE, cancer; HTN, liver disorders (eg, liver adenoma), DM w/ or w/o vascular involvement, cholelithiasis, migraine or severe headache, SLE, epilepsy, asthma, otosclerosis; CAD, cardiac dysfunction, ischaemic stroke; preexisting hypertriglyceridemia; hereditary & acquired angioedema. Temporarily withhold treatment for 4-6 wk if prolonged immobilisation is to follow elective surgery & not to be restarted until completely mobilised. Perform complete personal & family medical history & physical exam eg, pelvic & breast exam prior to therapy. Concomitant use w/ anticoagulants. Co-administration w/ ombitasvir/paritaprevir/ritonavir w/ or w/o dasabuvir; glecaprevir/pibrentasvir. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Renal dysfunction. Not indicated during pregnancy & lactation. Paed.

Headache; abdominal & back pain; breast pain/tenderness. Vag candidiasis; depression, nervousness; migraine, dizziness; nausea, vomiting, flatulence; allergic skin reactions eg, rash, urticaria, pruritus; menstrual disorders (eg, postmenopausal spotting, metrorrhagia, menorrhagia, oligo-/amenorrhoea, irregular menstruation, dysmenorrhoea), pelvic pain, cervical discharge; asthenic conditions eg, asthenia, fatigue, malaise, peripheral oedema; increased wt.

Increased metabolism by CYP450 inducers eg, anticonvulsants (phenobarb, carbamazepine, phenytoin) & anti-infectives (eg, rifampicin, rifabutin, nevirapine, efavirenz; ritonavir, nelfinavir. Induced metabolism by St. John's wort-containing herbal prep. Frequent ALT elevations w/ ombitasvir/paritaprevir/ritonavir w/ or w/o dasabuvir. Increased plasma levels of substrates w/ narrow therapeutic index eg, tacrolimus, cyclosporin A, fentanyl, theophylline.

Oestrogens, Progesterones & Related Synthetic Drugs

G03FB08 - dydrogesterone and estrogen ; Belongs to the class of progestogens and estrogens in sequential preparations.

C